To cite this paper use one of the standards below:
Combined Allergic Rhinitis and Asthma Syndrome (CARAS) is an airway disease that encompasses the clinical manifestations of allergic rhinitis and asthma with the same physiopathology. 4-carvomenthenol (Carvo) is a monoterpene of essential oils that exhibits anti-inflammatory activity. The goal of this study was to test the terpene on CARAS experimental model. BALB/c mice were submitted to the CARAS protocol and treated with 4-carvomentenol (100 - 50 mg/kg). The oral treatment with Carvo significantly reduced inflammatory cell migration mainly eosinophils to the nasal and pulmonary cavities and tissues, decreased the tissue remodeling, clinical signs of rhinitis as well as IgE-allergen specific and IL-13 production. Surprisingly the Carvo treatment increased the regulatory cytokine IL-10 level in the bronchoalveolar lavage. These preliminary data pointed out that the terpene presents anti-inflammatory property by up-regulating the regulatory immune response dependent on IL-10 in CARAS experimental model.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper